L3VLUP
ProSign in

STVN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

STVNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • STVN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSTVNVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20212 holders, $23m35 holders, $10.1bn
Q4 20214 holders, $15m28 holders, $12.4bn
Q1 20223 holders, $13m23 holders, $16.1bn
Q2 20221 holders, $791k25 holders, $18.1bn
Q3 20221 holders, $847k22 holders, $18.4bn
Q4 20221 holders, $898k28 holders, $18.4bn
Q1 20232 holders, $47m26 holders, $21.4bn
Q2 20233 holders, $117m27 holders, $24.7bn
Q3 20233 holders, $108m33 holders, $24.3bn
Q4 20233 holders, $115m32 holders, $28.6bn
Q1 20245 holders, $194m31 holders, $29.8bn
Q2 20244 holders, $121m29 holders, $33.4bn
Q3 20243 holders, $128m27 holders, $33.5bn
Q4 20243 holders, $153m26 holders, $28.5bn
Q1 20253 holders, $141m21 holders, $35.4bn
Q2 20253 holders, $177m21 holders, $32.3bn
Q3 20253 holders, $193m22 holders, $25.9bn
Q4 20253 holders, $144m26 holders, $31.8bn
Q1 20264 holders, $96m25 holders, $31.8bn
Q2 20263 holders, $160m26 holders, $34.6bn
STVN

Stevanato Group S P A

Holders
3
Reported value
$177m
Buyers
1
Sellers
1

Breadth 0 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only STVN (1)

Moore Capital Management LP

Only VRTX (19)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →